Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

Fig. 4

Comparison of the median decreases and cumulative decreases in TBIL levels between group A and group B and between group C and group D at different time points. a Median decrease in TBIL levels between group A and group B. b Cumulative decreases in TBIL levels between group A and group B. c Median decrease in TBIL levels between group C and group D. d Cumulative decreases in TBIL levels between group C and group D. Group A, liver failure patients treated with UCMSCs for more than 4 weeks (> 4 times); group B, liver failure patients treated with UCMSCs for less than or equal to 4 weeks (≤ 4 times). group C, liver cirrhosis patients treated with UCMSCs for more than 4 weeks (> 4 times); group D, liver cirrhosis patients treated with UCMSCs for less than or equal to 4 weeks (≤ 4 times). TBIL, total bilirubin. **P < 0.01

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512